| 证券代码：300630 | 证券简称：普利退 公告编号：2025-058 | | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | 海南普利制药股份有限公司 关于董事会提议向下修正可转换公司债券转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债券 （以下简称"可转债"）进入退市整理期的起始日为 2025 年 4 月 28 日，退市整 理期为十五个交易日，预计最后交易日期为 2025 年 5 月 21 日。公司股票及可 转债于退市整理期届满的次一交易日摘牌并终止上市。 2. 公司股票及可转债在退市整理期交易期间，公司将不筹划或实施重大资 产重组。可转债在退市整理期的相关交易规则、投资者适当性安排请投资者查阅 《关于可转换公司债券退市整理期间交易安排的通知》（深证上〔2023〕492 号） 及《关于完善可转换公司债券投资者适当性管理相关事项的通知（2025 年修订）》 （深证上〔2025〕223 号）。 3. 请投资者、证券公司等市场主体 ...

| 证券代码：300630 | 证券简称：普利退 | 公告编号：2025-057 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | | 海南普利制药股份有限公司 第四届董事会第三十九次会议决议 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"）进入退市整理期的起始日为 2025 年 4 月 28 日，退市 整理期为十五个交易日，预计最后交易日期为 2025 年 5 月 21 日。公司股票及 可转债于退市整理期届满的次一交易日摘牌并终止上市。 2. 公司股票及可转债在退市整理期交易期间，公司将不筹划或实施重大资 产重组。可转债在退市整理期的相关交易规则、投资者适当性安排请投资者查 阅《关于可转换公司债券退市整理期间交易安排的通知》（深证上〔2023〕492 号）及《关于完善可转换公司债券投资者适当性管理相关事项的通知（2025 年 修订）》（深证上〔2025〕223 号）。 3. 请投资者、证券公司等市场主体在 ...

| 证券代码：300630 | 证券简称：普利退 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | | 海南普利制药股份有限公司 关于公司股票及可转换公司债券进入退市整理期交易的 第六次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"），于退市整理期届满的次一交易日摘牌，公司股票及 可转债终止上市。 2. 公司股票及可转债进入退市整理期的起始日为 2025 年 4 月 28 日，预计 最后交易日期为 2025 年 5 月 21 日。 3. 公司股票及可转债将在退市整理期交易十五个交易日，截至 2025 年 5 月 16 日公司股票及可转债已交易 12 个交易日，剩余 3 个交易日，交易期满将 被终止上市，敬请投资者审慎投资、注意风险。 7. 公司股票已被调出深股通标的，深股通投资者只能卖出股票。后续公司 股票进入退市板块后，深股通投资者可能无法进行股票转让，提请深 ...

中证鹏元资信评估股份有限公司 中证鹏元公告【2025】224 号 根据公司于 2025 年 4 月 29 日披露的《关于再次延期披露会计差 错更正后的专项鉴证或审计报告的提示性公告》，因为公司前期会计 差错更正情况与中国证监会认定的虚假记载金额之间存在较大差异， 涉及的部分信息仍需进一步核实查清，但由于此次事项所涉及的工作 量较大，公司将延期至 2025 年 6 月 30 日前完成本次会计差错更正后 的专项鉴证或审计报告的披露工作。 根据公司于 2025 年 4 月 29 日披露的《关于预计无法在法定期限 内披露定期报告的风险提示公告》，鉴于财务报告数据有时间的关联 性与延续性，相关数据的准确性对 2024 年度审计报告中财务数据的 准确性具有强关联性，所涉及的部分信息尚需进一步核实查清，同时 因市场禁入决定，公司董事会及管理层均出现人员不足的情况，导致 公司预计无法在法定期限内（2025 年 4 月 30 日）披露 2024 年年度 报告及 2025 年第一季度报告。 截至 2025 年 5 月 7 日，"普利转退"余额为 2.0225 亿元，于 2025 年 2 月 9 日进入回售期，并于 2025 年 ...

| 证券代码：300630 | 证券简称：普利退 公告编号：2025-056 | | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | 海南普利制药股份有限公司 关于公司股票及可转换公司债券进入退市整理期交易的 第五次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"），于退市整理期届满的次一交易日摘牌，公司股票及 可转债终止上市。 7. 公司股票已被调出深股通标的，深股通投资者只能卖出股票。后续公司 股票进入退市板块后，深股通投资者可能无法进行股票转让，提请深股通投资 者注意投资风险。 8. 根据《退市公司可转换公司债券管理规定》第三十条，退市可转债自交 易所摘牌后至挂牌期间不得实施转股、赎回、回售等操作，挂牌后需重新提交 转股、赎回、回售等相关信息。 投资者已提交转股、赎回、回售等操作申请，摘牌前未实施完成的，需待 可转债在股转公司挂牌后重新提交操作申请，敬请投资者注意。 9. 终止上市后，公司的信息披露指定媒体 ...

Core Viewpoint - Hainan Puli Pharmaceutical Co., Ltd. has announced that its stock and convertible bonds will enter a delisting arrangement period, with the last trading day set for May 21, 2025, following a decision by the Shenzhen Stock Exchange to terminate their listing [1][2][4]. Group 1: Delisting Announcement - The company received a notice from the Shenzhen Stock Exchange on April 18, 2025, regarding the termination of its stock and convertible bonds listing [2]. - The delisting arrangement period began on April 28, 2025, lasting for fifteen trading days, with the final trading day expected to be May 21, 2025 [4][5]. - During the delisting period, the stock will be traded on the risk warning board of the Shenzhen Stock Exchange, with no price fluctuation limits on the first trading day, followed by a 20% limit on subsequent days [3][4]. Group 2: Trading Rules and Restrictions - The stock and convertible bonds will not be subject to price fluctuation limits on the first trading day of the delisting period, but will have a 20% limit thereafter [3][4]. - Investors are advised that after the delisting, they will not be able to execute conversion, redemption, or repurchase operations until the bonds are listed again [2][5]. - The company will not plan or implement any major asset restructuring during the delisting period [5]. Group 3: Investor Communication - The company will issue risk warning announcements regarding the delisting every five trading days during the first ten trading days and daily during the last five trading days of the delisting period [4]. - Investors are encouraged to refer to the official announcements published on the designated information disclosure media for accurate information [6].

| 证券代码：300630 | 证券简称：普利退 | 公告编号：2025-055 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | | 海南普利制药股份有限公司 关于公司股票及可转换公司债券进入退市整理期交易的 第四次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"），于退市整理期届满的次一交易日摘牌，公司股票及 可转债终止上市。 2. 公司股票及可转债进入退市整理期的起始日为 2025 年 4 月 28 日，预计 最后交易日期为 2025 年 5 月 21 日。 3. 公司股票及可转债将在退市整理期交易十五个交易日，截至 2025 年 5 月 14 日公司股票及可转债已交易 10 个交易日，剩余 5 个交易日，交易期满将 被终止上市，敬请投资者审慎投资、注意风险。 4. 公司股票及可转债在退市整理期交易期间，公司将不筹划或实施重大资 产重组。可转债在退市整理期的相关交易规则、投资者适当性安排请 ...

New Stock Offerings - ST Xinchao (600777) is in the offer period from April 23, 2025, to May 22, 2025[1] - Polytron Technologies (300630) has 5 trading days remaining until the last trading day[1] - ST Cube (300344) has an announcement dated May 14, 2025, but no specific details provided[1] Trading Alerts - ST Zhongcheng (300208) reported severe abnormal fluctuations on April 29, 2025[1] - ST Hu Ke (600608) and ST Hua Rong (600421) both have announcements dated May 14, 2025, with no further details[1] - ST Zhengping (603843) has an announcement dated May 13, 2025, with no specific details provided[1] Market Trends - Multiple stocks, including ST Yanzhen (603389) and ST Chuangxing (600193), have announcements dated May 14, 2025, indicating potential market volatility[1] - The report highlights a significant number of stocks under observation for abnormal trading activities, suggesting increased market scrutiny[2]

Investment Rating - The report maintains a "Recommended" rating for the healthcare sector [6]. Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11]. - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13]. - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16]. Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 sectors [2][11]. - The year-to-date performance shows a 1.19% increase, ranking 15th among the sectors [13]. 2. Key Company Announcements - Key companies such as Kelly Tai, BGI Genomics, and Dongfang Bio reported varying financial results, with some showing significant declines in net profit [21]. 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22]. - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22]. - The report suggests that the innovative drug sector is entering a phase of realization, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22]. 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%), Haichuang Pharmaceutical (+25.85%), and Jinhao Medical (+25.32%) [3][20]. - Conversely, the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20].

Group 1 - Longjiang Transportation plans to reduce its shareholding by no more than 3% of the company's total shares, amounting to 39.4764 million shares, from June 4, 2025, to September 3, 2025 [1] - Shuangyi Technology intends to acquire 100% equity of Marky Industries Pty Ltd and specific assets for approximately AUD 18 million [1] - Haikong Air Conditioning's controlling shareholder has received a bank loan commitment of up to CNY 32 million for share repurchase [2] Group 2 - Zhaowei Electromechanical's shareholder plans to reduce its stake by no more than 1.50%, equating to 3.6031 million shares, from June 5, 2025, to September 4, 2025 [2] - Zhongwen Online's directors and senior management plan to collectively reduce their holdings by no more than 877,100 shares, representing 0.1203% of the total shares [2] - Liding Optoelectronics' shareholders plan to reduce their holdings by no more than 3%, totaling 12.2113 million shares, from June 5, 2025, to September 4, 2025 [4] Group 3 - Luvi Optoelectronics' shareholder plans to reduce its stake by no more than 1%, amounting to 1.9333 million shares, from June 4, 2025, to September 4, 2025 [5] - Jiejia Weichuang's controlling shareholder and concerted parties plan to reduce their holdings by no more than 0.72%, totaling 250,000 shares [7] - Yancoal Energy will no longer acquire control of Highfield Resources due to a new investment from Qinghai Salt Lake Industry Co., Ltd. [9] Group 4 - Yongdong Co., Ltd. plans to reduce its shareholding by no more than 1.26%, equating to 473,380 shares, from June 5, 2025, to September 4, 2025 [11] - Sanqi Interactive Entertainment plans to distribute a cash dividend of CNY 2.10 per 10 shares [12] - Salt Lake Co., Ltd. intends to acquire Highfield Resources for approximately USD 300 million to become its largest shareholder [13] Group 5 - Hainan Haiyao's shareholder plans to reduce its stake by no more than 3%, totaling 38.921 million shares, within 90 days after the announcement [14] - Lifang Pharmaceutical plans to transfer 2.2184% equity of Nanjing Mainowei Pharmaceutical Technology Co., Ltd. for CNY 22.1837 million [16] - Zhiyou Technology's shareholders plan to reduce their holdings by no more than 2.99%, totaling 11.9986 million shares, from June 4, 2025, to September 3, 2025 [18] Group 6 - Puli Tui has applied for a review of the Shenzhen Stock Exchange's decision to terminate its listing [19] - Saimo Intelligent's shareholder plans to reduce its stake by no more than 3%, equating to 16.0659 million shares, from June 4, 2025, to September 3, 2025 [20] - Entropy Technology is planning to acquire 55% equity of Longzhiyuan to gain control [21] Group 7 - Nanjing Chemical Fiber plans to acquire 100% of Nanjing Process Equipment Manufacturing Co., Ltd. through asset swaps and cash payments [22] - Beijing Lier intends to invest CNY 200 million in Shanghai Zhenliang Intelligent Technology Co., Ltd. [23]